159 related articles for article (PubMed ID: 36633506)
1. iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.
Lajara R; Heller C; Pantalone KM; Lew E; Li X; Dex T; Kilpatrick CR
Diabetes Obes Metab; 2023 May; 25(5):1249-1260. PubMed ID: 36633506
[TBL] [Abstract][Full Text] [Related]
2. Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.
Pantalone KM; Heller C; Lajara R; Lew E; Li X; Dex T; Kilpatrick CR
Diabetes Spectr; 2023; 36(3):253-263. PubMed ID: 37583559
[TBL] [Abstract][Full Text] [Related]
3. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
[No Abstract] [Full Text] [Related]
4. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
5. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
[TBL] [Abstract][Full Text] [Related]
6. Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
Frechtel G; Sauque-Reyna L; Choza-Romero R; Anguiano L; Melas-Melt L; Sañudo-Maury ME
Diabetes Obes Metab; 2023 Sep; 25(9):2526-2534. PubMed ID: 37253689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
8. iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.
McCrimmon RJ; Cheng AYY; Galstyan G; Djaballah K; Li X; Coudert M; Frias JP
Diabetes Obes Metab; 2023 Jan; 25(1):68-77. PubMed ID: 36123617
[TBL] [Abstract][Full Text] [Related]
9. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
[TBL] [Abstract][Full Text] [Related]
11. Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Yang W; Guo X; Lauand F; Li L; Fang H; Du Q; Kang L
Diabetes Obes Metab; 2024 Apr; 26(4):1197-1206. PubMed ID: 38172083
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
McCrimmon RJ; Home P; Cheng A; Giorgino F; Fonseca V; Souhami E; Alvarez A; Picard P; Rosenstock J
Diabetes Obes Metab; 2022 Dec; 24(12):2391-2399. PubMed ID: 36054624
[TBL] [Abstract][Full Text] [Related]
13. iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
Guja C; Kis JT; Haluzík M; Bonnemaire M; Bigot G; Tournay M; Freemantle N; Seufert J
Diabetes Obes Metab; 2023 Jun; 25(6):1723-1730. PubMed ID: 36810874
[TBL] [Abstract][Full Text] [Related]
14. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
Polonsky WH; Giorgino F; Rosenstock J; Whitmire K; Lew E; Coudert M; Alvarez A; Nicholls C; McCrimmon RJ
Diabetes Obes Metab; 2022 Dec; 24(12):2364-2372. PubMed ID: 36053820
[TBL] [Abstract][Full Text] [Related]
15. Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
Munshi M; Ritzel R; Jude EB; Dex T; Melas-Melt L; Rosenstock J
Diabetes Obes Metab; 2024 Mar; 26(3):851-859. PubMed ID: 38082473
[TBL] [Abstract][Full Text] [Related]
16. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
[TBL] [Abstract][Full Text] [Related]
17. Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Home PD; McCrimmon RJ; Rosenstock J; Blüher M; Pegelow K; Melas-Melt L; Djaballah K; Giorgino F;
Diabetes Obes Metab; 2023 Mar; 25(3):656-663. PubMed ID: 36309941
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
19. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
McCrimmon RJ; Al Sifri S; Emral R; Mohan V; Sauque-Reyna L; Trescolí C; Lalic N; Alvarez A; Demil N; Coudert M; Shaunik A; Bonnemaire M; Rosenstock J;
Diabetes Obes Metab; 2021 Jun; 23(6):1221-1231. PubMed ID: 33606908
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
